Association between selenium intake and the risk of pancreatic cancer: a meta-analysis of observational studies

Abstract

Quantification of the association between the intake of selenium and risk of pancreatic cancer is still conflicting. Thus, we conducted a meta-analysis to summarize the evidence from epidemiological studies of selenium intake with the risk of pancreatic cancer. Pertinent studies were identified by a search of PubMed and Web of Knowledge to July 2016. The random-effect model was used. Sensitivity analysis and publication bias were conducted. Data from six studies including 1424 pancreatic cancer cases were used in this meta-analysis. Pooled results suggested that highest selenium intake amount compared with lowest amount was significantly associated with the risk of pancreatic cancer [summary relative risk (RR)=0.659, 95% confidence interval (CI)=0.489–0.889, I2=47.6%]. The associations were significant both in case–control studies [RR=0.618, 95%CI=0.399–0.956, I2=59.1%] and Americas [RR=0.570, 95%CI=0.357–0.909, I2=65.6%]. No publication bias was found. Our analysis suggested that the higher intake of selenium might reduce the risk of pancreatic cancer.

Long-Term Dietary Supplementation with Selenium-Enriched Yeast Improves Cognitive Impairment, Reverses Synaptic Deficits, and Mitigates Tau Pathology in a Triple Transgenic Mouse Model of Alzheimer’s Disease

“…Compared with inorganic Se, Se-yeast is less toxic, exhibits higher bioavailability, and can maintain Se levels for a longer period after the cessation of supplementation . Currently, Se-yeast is mainly used to treat Keshan disease, prevent cancer, or modulate immune responses. − On the basis of our previous studies, Se-Met, the major form of Se in Se-enriched yeast, effectively improved cognitive dysfunction and neuropathology in the triple transgenic mouse model of AD (3×Tg-AD mice). , These studies of the effects of the Se compound on subjects with AD indicated that Se-yeast has great potential as a treatment for AD, but the exact effects and underlying mechanisms remain poorly understood. In this study, we explored the effect of Se-yeast on AD pathology and found that long-term dietary supplementation with Se-yeast improved the cognitive abilities of 3×Tg-AD mice by reducing tau hyperphosphorylation, improving neuronal activity, and mitigating synaptic deficits, revealing a therapeutic effect of Se-yeast on a mouse model of AD.…”

LRRC19—A Bridge between Selenium Adjuvant Therapy and Renal Clear Cell Carcinoma: A Study Based on Datamining

“…Although the relationship between selenium and tumors has been widely reported in epidemiological studies [36][37][38][39][40], the evidence of taking selenium as an anticancer drug alone seems to be insufficient. Reports of MSC have described the anti-tumor effect associated with irinotecan through the affection of the tumor microenvironment (TME), including the inhibition of angiogenesis [29].…”

Integrative Management of Pancreatic Cancer (PDAC): Emerging Complementary Agents and Modalities

“…Han X et al originally reported anti-PDAC effects of selenium (128,129). A meta-analysis and a later nested case-control study found no adverse effect on PDAC but a negative association was apparent for patients with body mass index (BMI) higher than 25 (130,131). Beneficial effects and no adverse effects have also been reported against diabetes (132)(133)(134).…”